Ambra Taylor, OTR | |
4355 Yarrow Ln, Johnstown, CO 80534-6411 | |
(970) 663-4247 | |
Not Available |
Full Name | Ambra Taylor |
---|---|
Gender | Female |
Speciality | Occupational Therapist |
Location | 4355 Yarrow Ln, Johnstown, Colorado |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1679915870 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | 0003687 (Colorado) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ambra Taylor, OTR 4355 Yarrow Ln, Johnstown, CO 80534-6411 Ph: (970) 663-4247 | Ambra Taylor, OTR 4355 Yarrow Ln, Johnstown, CO 80534-6411 Ph: (970) 663-4247 |
News Archive
According to federal advisors last Thursday, obesity drugs should undergo clinical trials to ensure that they do not cause heart attacks. This would make it harder for these drugs to receive approval.
Australian Medical Association President, Dr Bill Glasson, said yesterday that the Government's decision to extend the Medicare safety net to cover out-of-hospital private obstetrics services would ease the financial burden on pregnant women and their families.
Researchers at the Cedars-Sinai Heart Institute have found that injections of cardiac stem cells might help reverse heart damage caused by Duchenne muscular dystrophy, potentially resulting in a longer life expectancy for patients with the chronic muscle-wasting disease.
A new study published yesterday in the Journal of the National Cancer Institute suggests that, in comparison with just screening women who are at high risk of carrying breast and ovarian cancer gene mutations, screening the entire population for these mutations will be more cost-effective.
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
› Verified 3 days ago
Dona Jean Leonard, MS, OTR, CEASII Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4921 Saddlewood Cir, Johnstown, CO 80534 Phone: 970-420-6049 Fax: 970-200-8359 | |
Carolyn Rose Coates, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4435 Ronald Reagan Blvd, Johnstown, CO 80534 Phone: 650-380-4504 | |
Bauer Occupational Therapy, Llc Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 442 La Costa Ln, Johnstown, CO 80534 Phone: 970-590-6827 | |
Mandie Schake, MOTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 4401 Union St, Johnstown, CO 80534 Phone: 970-619-3400 |